Institute for Applied Cancer Science
RESEARCH PLATFORM FOR
THE MOON SHOTS PROGRAM
The mission of the Institute for Applied Cancer Science (IACS) is to apply scientific knowledge of mechanisms driving tumor development and maintenance into the development of impactful small molecule cancer therapies.
Embedded within MD Anderson’s culture of innovative academic science and clinical excellence, the institute aligns drug discovery and development research directly with the world-class science and clinical care for which MD Anderson is known. The mission is to bring novel, more effective therapeutics to patients. The first, IACS-10759, is already in clinical trials and several new drugs are expected to enter clinical testing in 2018.
The Institute’s synergistic approach relies on three key components:
- A highly experienced team of professional drug discovery and development scientists
- Real-time access to insights gained
by the best physician-scientists in the nation, who treat more than
120,000 cancer patients per year
informed, patient-oriented research programs that are focused on
delivering impactful results to patients
New company to develop neuroprotective therapies
MD Anderson and Accelerator Life Science Partners have joined together to launch a new company called Magnolia Neurosciences Corporation. The company will develop a new class of neuroprotective medicines based on discoveries made by researchers in the Therapeutics Discovery division, including Institute for Applied Cancer Sciences (IACS) and the Neurodegeneration Consortium.
Drug targeting tumor metabolism enters clinical trial
MD Anderson’s Institute for Applied Cancer Science (IACS) initiated the first clinical study of a novel drug designed to starve cancer cells, IACS-10759. The study will enroll patients with acute myeloid leukemia (AML) and is supported by a $3.5 million investment from The Leukemia & Lymphoma Society (LLS) Therapy Acceleration Program®. Recent approval from the U.S. Food and Drug Administration to begin clinical studies was based on compelling activity upon IACS-10759 treatment in multiple preclinical models of AML.
New bench-to-bedside cancer drug development partnership
MD Anderson and BridgeBio Pharma announce launch of Navire Pharma
Established in November 2011, IACS has been operational since January 2012. Since then, the Institute has built a state-of-the-art laboratory from the ground up, recruited a staff of talented scientists with proven track records in drug discovery and development, and developed a portfolio of projects that are being driven aggressively toward the clinic.
The first of these, IACS-010759, an inhibitor of oxidative phosphorylation for the treatment of acute myeloid leukemia, has completed GLP-toxicology studies and an Investigational New Drug (IND) application, was approved by the U.S. Food and Drug Administration during summer 2016 and has entered into a Phase I clinical trial at MD Anderson. Trials in solid tumors are expected to be introduced in the fall 2017.
IACS-6274 is another selected clinical candidate for a second undisclosed cancer metabolism target that is being developed in partnership with two Moon Shot™ disease sites. This drug is expected to enter the clinic in spring 2018, with several others following rapidly behind.
The Institute has integrated capabilities in cancer biology, medicinal chemistry, in vitro and in vivo pharmacology, structural biology and computational chemistry, animal modeling, computational and systems biology, as well as translational medicine. Together with the research and clinical resources of the nation’s leading cancer hospital, we have the ability to take a program from a research hypothesis all the way to a clinical candidate supported by robust preclinical data, and into early phase clinical studies in well-defined patient populations.
IACS projects include drug discovery in the areas of cancer metabolism, epigenetics and signal transduction. These projects are weighed through a consideration of not only clinical impact and scientific merit but also technical feasibility. Specific factors considered in the selection criteria for each target include:
- Disease relevance — including the dependency of specific cancer cells for this protein
- Ease of therapeutic attack — especially the probability of finding a suitable molecule for proof-of-concept pharmacological studies in a timely manner
- Clinical need — emphasis on cancer subtypes where no therapy is currently available
The Institute is currently advancing multiple drug discovery programs aimed at delivering clinical candidates in a timely manner. These candidates are either wholly owned by MD Anderson or collaboratively owned through our partnered programs. In addition, we have a robust a pipeline of earlier stage programs. The nature of our work is collaborative: we work with MD Anderson investigators and have also successfully partnered with external pharmaceutical companies and foundations for some of our ongoing development programs. We will continue to forge partnerships with external parties so that, together, we can advance the most promising novel therapeutic candidates into the clinic to help patients.
TESARO, Inc., an oncology focused biopharmaceutical company, and IACS announced an exclusive collaboration to discover and develop small molecule product candidates against undisclosed immuno-oncology targets.
MD Anderson and Deerfield Management create Vescor LLC
Vescor LLC, a new company focused on discovery and development of autophagy targeted therapeutics for cancer treatment, has been formed by MD Anderson Cancer Center, Deerfield Management and two leading autophagy experts. In combination with Deerfield, the IACS Moon Shot™ platform will provide drug discovery and development expertise, together with translational research focused at advancing autophagy therapeutics into trials in melanoma, lung and pancreatic cancers.